Radar · Life Sciences in Maryland
Best Life Sciences Companies in Maryland, United States
The 516 best Life Sciences companies in Maryland, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Novavax.
By Riya SenguptaFinancials
516companies tracked
$11.5Bdisclosed funding
0unicorns
299have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × MARYLAND
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
164companies analysed
83%cloud-native stacks
2025funding peak (by rounds)
7unicorns
2016median founding year
182kcombined LinkedIn audience
61%of audience held by top 3
5companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Maryland
| # | Company | Disclosed funding | Last round | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|
| 1 | Novavax Developer of novel vaccines for the treatment of infectious diseases 83Product top 14%Patents top 17%Funding top 22%Innovation top 23% All 13 signals ▾Producttop 14% Patentstop 17% Fundingtop 22% Innovationtop 23% Partnerstop 26% Markettop 28% Moattop 29% Fin. healthtop 32% Globaltop 35% Growthtop 37% Newstop 40% Techtop 41% Talentbottom 48% Product: 4 distinct product lines · Company stage: Public Patents: 599 patents matched (strict assignee match) · 193 filings since 2022 vs 135 in 2017-21 rank vs industry peers · Fliar Intelligence Index 83/100 | $2.7B | 33 mo ago | 184 | John Jacobs President | 599 patents Patents concentrated in chemistry & materials | 2 launchs · 2 partnerships |
| 2 | Delfi Diagnostics Provider of DNA sequencing for cancer detection 67Funding top 17%Patents top 24%AI top 28%Moat top 28% All 11 signals ▾Fundingtop 17% Patentstop 24% AItop 28% Moattop 28% Innovationtop 32% Talenttop 42% Growthtop 48% Marketbottom 49% Techbottom 47% Globalbottom 36% Newsbottom 33% Funding: Raised $332M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) Patents: 52 patents matched (strict assignee match) · 52 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $332M | 6 mo ago | 197 | Victor Velculescu Founder and Board of Directors | 52 patents Non-invasive cancer detection and monitoring via cell‑free DNA fragmentation profiling | 1 job opening · 1 partnership · 3 awards |
| 3 | Sirnaomics Developer of RNA based therapeutics for the treatment of cancer and fibrosis disease 80Patents top 14%Funding top 15%Innovation top 17%Growth top 28% All 9 signals ▾Patentstop 14% Fundingtop 15% Innovationtop 17% Growthtop 28% Moattop 35% Markettop 46% Talentbottom 49% Globalbottom 48% Newsbottom 21% Patents: 277 patents matched (strict assignee match) · 191 filings since 2022 vs 63 in 2017-21 Funding: Raised $267M across 14 rounds · 14 rounds over 19 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 80/100 | $267M | 9 mo ago | 88 | Patrick Lu President and CEO | 277 patents siRNA therapeutics and nanoparticle delivery systems for cancer and viral diseases | 1 launch |
| 4 | Barinthus Biotherapeutics Developer of T-cell immunotherapeutics to treat multiple diseases | $210M | 29 mo ago | — | Adrian Hill Co-Founder | 33 patents Peptide vaccine nanocarriers for cancer immunotherapy and targeted drug delivery | — |
| 5 | Sanaria Developer of whole-parasite malaria vaccines for infectious diseases 48Funding top 23%Patents top 33%Moat top 41%Innovation top 46% All 8 signals ▾Fundingtop 23% Patentstop 33% Moattop 41% Innovationtop 46% Growthtop 47% Marketbottom 44% Techbottom 44% Globalbottom 37% Funding: Raised $188M across 44 rounds · 44 rounds over 21 yrs (2.1/yr) Patents: 134 patents matched (strict assignee match) · 16 filings since 2022 vs 46 in 2017-21 rank vs industry peers · Fliar Intelligence Index 48/100 | $188M | 9 mo ago | 77 | — | 134 patents Malaria vaccine production, sporozoite cryopreservation, and vector storage technologies | — |
| 6 | Clasp Therapeutics Developer of T cell therapeutics for the treatment of cancer | $150M | 26 mo ago | — | Shibin Zhou Co-Founder | — | 1 award |
| 7 | Immunomic Therapeutics Vaccines for allergy, cancer and infectious disease. 57Funding top 24%Growth top 28%Product top 30%Innovation top 34% All 9 signals ▾Fundingtop 24% Growthtop 28% Producttop 30% Innovationtop 34% Moattop 39% Techbottom 44% Marketbottom 37% Globalbottom 37% Newsbottom 21% Funding: Raised $97.9M across 14 rounds · 14 rounds over 15 yrs (0.9/yr) Growth: Headcount 38 → 51 (+34%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 57/100 | $98M | 12 mo ago | 51 | — | — | — |
| 8 | TissueGene Developer of regenerative therapies for orthopedic diseases | $95M | 24 mo ago | 58 58 → 80 (+38%) · sector median +28% | Moon Noh CEO | 83 patents Regenerative cell/gene therapies for nerve, disc repair and immune‑mediated inflammation | 9 job openings |
| 9 | Promaxo Developer of portable MRI for the cancer diagnostics market | $72M | 3 mo ago | 22 22 → 55 (+150%) · sector median +28% | Irving Weinberg Co-Founder | 212 patents Patents concentrated in computing, sensing & instrumentation | — |
| 10 | CASI Pharmaceuticals Developer of therapeutics for the treatment of cancer 60Product top 19%Funding top 26%Growth top 36%Innovation top 38% All 10 signals ▾Producttop 19% Fundingtop 26% Growthtop 36% Innovationtop 38% Fin. healthtop 43% Markettop 46% Moatbottom 49% Globalbottom 44% Newsbottom 41% Techbottom 33% Product: 3 distinct product lines · Company stage: Public Funding: Raised $69.5M across 5 rounds · 5 rounds over 20 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $69M | 5 mo ago | 234 | — | — | — |
| 11 | Nuo Therapeutics Developer of regenerative products for wound care 53Growth top 11%Funding top 24%Talent top 45%Fin. health top 50% All 9 signals ▾Growthtop 11% Fundingtop 24% Talenttop 45% Fin. healthtop 50% Moatbottom 38% Globalbottom 37% Marketbottom 33% Techbottom 30% Newsbottom 21% Growth: Revenue +143% YoY · Fresh capital in last 24 mo Funding: Raised $64.6M across 18 rounds · 18 rounds over 16 yrs (1.1/yr) rank vs industry peers · Fliar Intelligence Index 53/100 | $65M | 10 mo ago | 10 10 → 19 (+90%) · sector median +28% | David Jorden CEO & Director | — | — |
| 12 | Gliknik Discovering and developing innovative biologics for immune disorders and cancers 22Funding top 21%Moat top 21%Product top 25%Patents top 31% All 9 signals ▾Fundingtop 21% Moattop 21% Producttop 25% Patentstop 31% Innovationtop 33% Globalbottom 36% Newsbottom 22% Marketbottom 20% Techbottom 16% Funding: Raised $60.3M across 12 rounds · 12 rounds over 16 yrs (0.8/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 246 patents rank vs industry peers · Fliar Intelligence Index 22/100 | $60M | 10 mo ago | 6 | — | 246 patents Engineered multimeric Fc fusion proteins for enhanced complement activation and therapeutic antibodies | — |
| 13 | Medcura Developer of the device for controlling bleeding | $59M | 14 mo ago | 24 | — | 38 patents Hydrophobically-modified polymer hemostatic and anti-adhesion medical devices | — |
| 14 | American Gene Developer of lentivirus therapies for the treatment of cancer and other chronic human diseases 55Funding top 24%Patents top 31%Moat top 35%Talent top 35% All 11 signals ▾Fundingtop 24% Patentstop 31% Moattop 35% Talenttop 35% Innovationtop 37% Growthtop 40% Producttop 40% Techtop 46% Marketbottom 36% Globalbottom 36% Newsbottom 22% Funding: Raised $52.8M across 10 rounds · 10 rounds over 13 yrs (0.8/yr) Patents: 228 patents matched (strict assignee match) · 90 filings since 2022 vs 138 in 2017-21 rank vs industry peers · Fliar Intelligence Index 55/100 | $53M | 7 mo ago | 31 | Jeff Galvin Chief Executive Officer | 228 patents Non-integrating viral vectors for gene delivery and HIV immunotherapy, plus gamma‑delta T‑cell activation | — |
| 15 | OncoC4 Developer of immunotherapy for cancer patients 62Patents top 17%Innovation top 21%Funding top 28%Moat top 33% All 7 signals ▾Patentstop 17% Innovationtop 21% Fundingtop 28% Moattop 33% Globalbottom 43% Marketbottom 42% Newsbottom 34% Patents: 128 patents matched (strict assignee match) · 115 filings since 2022 vs 13 in 2017-21 Innovation: 128 patents (top 15% of patent-holders) · 115 filings since 2022 vs 13 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $52M | 8 mo ago | 41 | — | 128 patents Immune checkpoint antibody therapeutics, especially anti‑CTLA‑4 combos for cancer treatment | 1 job opening |
| 16 | Abvacc Developer of vaccines and therapeutics to treat infectious diseases 35Funding top 30%Moat top 38%Patents top 43%Innovation top 50% All 7 signals ▾Fundingtop 30% Moattop 38% Patentstop 43% Innovationtop 50% Talentbottom 49% Marketbottom 37% Globalbottom 31% Funding: Raised $45.5M across 10 rounds · 10 rounds over 3 yrs (3.3/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 6 patents rank vs industry peers · Fliar Intelligence Index 35/100 | $46M | 12 mo ago | — | M Aman Founder | 6 patents Vaccines targeting bacterial toxins and cell‑wall domains for immunotherapy | — |
| 17 | Infinite Biomedical Innovative upper limb myoelectric solutions improving lives through advanced technology 48Growth top 35%Funding top 38%Innovation top 39%AI top 45% All 8 signals ▾Growthtop 35% Fundingtop 38% Innovationtop 39% AItop 45% Techtop 46% Producttop 46% Globalbottom 32% Marketbottom 21% Growth: Fresh capital in last 24 mo Funding: Raised $42.3M across 18 rounds · 18 rounds over 28 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 48/100 | $42M | 12 mo ago | 11 | — | — | 1 job opening · 1 launch |
| 18 | CraniUS A medical technology company developing drug delivery systems to treat brain diseases and disorders 64Patents top 23%Innovation top 28%Funding top 31%Moat top 34% All 7 signals ▾Patentstop 23% Innovationtop 28% Fundingtop 31% Moattop 34% Talenttop 38% Globaltop 48% Marketbottom 49% Patents: 47 patents matched (strict assignee match) · 47 filings since 2022 vs 0 in 2017-21 Innovation: 47 patents (top 32% of patent-holders) · 47 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $42M | 4 mo ago | — | Chad Gordon Founder & CMO | 47 patents Implantable medical devices with flexible catheters, drug delivery, and wireless power management | — |
| 19 | WaveGuide Portable micro-nuclear magnetic resonance instruments for on-site testing and analysis | $41M | 13 mo ago | 6 | Gregg Hershenson Co-Founder | 26 patents Low-field NMR instrumentation with advanced programmable-gain and switched-mode amplifiers | — |
| 20 | Sonavex Provider of ultrasound based imaging for Intraoperative detection of anastomotic blood clots | $31M | 19 mo ago | 12 12 → 24 (+100%) · sector median +28% | — | 13 patents Ultrasound-guided vascular imaging and cannulation; echogenic polymer devices for medical ultrasound. | — |
| 21 | FZata Developer of biologics for gastrointestinal disorders treatment | $29M | 13 mo ago | 6 | — | 20 patents Engineered yeast therapeutics and TNF‑α binding protein/antibody biologics for pain and infection | — |
| 22 | Scanogen Provider of single-molecule biosensors for cancer diagnostics 29Talent top 28%Moat top 32%Funding top 33%Patents top 35% All 9 signals ▾Talenttop 28% Moattop 32% Fundingtop 33% Patentstop 35% Innovationtop 42% Productbottom 44% Globalbottom 35% Techbottom 28% Marketbottom 21% Talent: Analyst team rating 4/5 Moat: Editorial + unicorn rating 4/10 · IP moat: 26 patents rank vs industry peers · Fliar Intelligence Index 29/100 | $29M | 10 mo ago | 7 | — | 26 patents Biosensor and imaging technologies for rapid medical analyte detection and diagnostics | — |
| 23 | Rapafusyn Developer of therapeutics for treatment of multiple diseses | $28M | 9 mo ago | 3 | Sean Hu CEO | — | — |
| 24 | Cellphire Therapeutics Developer of platelet-derived therapeutics to address bleeding control and hemostasis challenges | $25M | 6 mo ago | 51 51 → 48 (-6%) · sector median +28% | Mike Gaffney CEO | — | — |
| 25 | Antidote Therapeutics Developing nicotine-blockers to treat diseases caused by nicotine and addiction | $22M | 13 mo ago | 3 | Matthew Kalnik Founder & CEO | — | — |
| 26 | Longeviti Developer of implantable neurosurgical devices | $17M | 17 mo ago | 18 | — | — | 1 launch · 1 award |
| 27 | CoapTech Developer of a minimally invasive method for the placement of gastrostomy feeding tubes into stomachs of… | $17M | 21 mo ago | 25 | — | 42 patents Medical tube placement and verification in gastrointestinal and thoracoabdominal cavities | — |
| 28 | Sigmovir Developing the cotton rat as a model for human infectious disease research | $15M | 22 mo ago | 13 | Kevin Yim Co-founder | — | — |
| 29 | Alphyn Biologics Developer of therapeutics for severe and common skin diseases 27Patents top 28%Moat top 32%Innovation top 33%Funding top 37% All 7 signals ▾Patentstop 28% Moattop 32% Innovationtop 33% Fundingtop 37% Techbottom 43% Globalbottom 40% Marketbottom 16% Patents: 30 patents matched (strict assignee match) · 21 filings since 2022 vs 9 in 2017-21 Moat: Editorial + unicorn rating 4/10 · IP moat: 30 patents rank vs industry peers · Fliar Intelligence Index 27/100 | $13M | 6 mo ago | 3 | — | 25 patents Topical antibacterial skin treatments using croton lechleri-derived pharmaceutical compositions | — |
| 30 | AgeneBio Therapeutic to treat amnestic mild cognitive impairment (aMCI) due to Alzheimer’s disease. | $12M | 9 mo ago | 1 | — | 203 patents Novel CNS therapeutics: benzodiazepine derivatives and extended‑release levetiracetam for cognitive disorders | — |
| 31 | Creative Bio-Peptides Developer of oral peptide treatments for neurodegenerative diseases | $11M | 12 mo ago | — | Michael Ruff Founder & CEO | — | — |
| 32 | VerImmune Developer of vaccines for the treatment of cancer | $10M | 13 mo ago | 7 | John Troyer Founder & COO | 36 patents Virus-like particle-based cancer immunotherapies that redirect antigen-specific immune responses | 1 award |
| 33 | Flavocure Biotech Developing next-generation oncology solutions inspired by nature for cancer treatment | $8M | 16 mo ago | — | Henry Lowe Co-Founder | — | — |
| 34 | OS Therapies Developer of therapies for treating cancer | $8M | 3 mo ago | 5 | Paul Romness CEO | 10 patents Ocular drug delivery formulations and handheld thermal devices for eye surface disorders | — |
| 35 | Elixirgen Therapeutics Developer of RNA therapeutics to treat multiple diseases 9Funding top 37%Talent bottom 49%Global bottom 37%Market bottom 21% All 5 signals ▾Fundingtop 37% Talentbottom 49% Globalbottom 37% Marketbottom 21% Techbottom 18% Funding: Raised $7.3M across 11 rounds · 11 rounds over 14 yrs (0.8/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 9/100 | $7M | 7 mo ago | 11 11 → 13 (+18%) · sector median +28% | Minoru Ko Co-Founder | — | — |
| 36 | Zero Point Five Therapeutics Developer of therapeutics for infectious diseases | $7M | 14 mo ago | — | Joseph Amprey Co-Founder & CEO | — | — |
| 37 | SilcsBio Provides software and services for computer driven drug design | $7M | 14 mo ago | 7 | — | — | — |
| 38 | AccelevirDx Developer of diagnostic assays for HIV | $7M | 14 mo ago | 8 | Albine Martin Co-Founder/Investor | — | — |
| 39 | miRecule Developing microRNA therapies for the treatment of cancers | $5M | 9 mo ago | 8 | Anthony Saleh Co-Founder & CEO | 52 patents Muscle‑targeted imaging agents and nucleic‑acid therapeutics for neuromuscular disorders | 1 award |
| 40 | OncoSTING Developer of immunotherapy for bladder cancer | $5M | 6 mo ago | 3 | William Bill Bishai Co-Founder | — | — |
| 41 | Optosurgical Developer of intraoperative imaging devices designed to aid clinicians during surgery | $4M | 13 mo ago | — | Richard Cha Founder | 2 patents AI-driven biometric tissue imaging and physiological data extraction for medical diagnostics | — |
| 42 | Pearl Diagnostics Foundation focused on detection and prevention of fungal infections 13Funding top 35%Talent bottom 49%Global bottom 32%Market bottom 20% All 4 signals ▾Fundingtop 35% Talentbottom 49% Globalbottom 32% Marketbottom 20% Funding: Raised $3.5M across 5 rounds · 5 rounds over 4 yrs (1.2/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 13/100 | $4M | 3 mo ago | 6 | Kieren Marr Founder & CEO | — | — |
| 43 | Iyuda Therapeutics Developer of medicines for the treatment of multiple conditions | $3M | 2 mo ago | — | William Sargent Jr. Founder & Chief Business Officer | — | — |
| 44 | Auscultech Dx Developer of computer-aided auscultation for pediatric applications | $2M | 13 mo ago | — | Robin Doroshow Co-Founder and Chief Medical Officer | 3 patents AI-driven throat imaging diagnostics and digital stethoscope signal analysis for respiratory health | — |
| 45 | DFH Pharma Developer of pharmaceutical products, focusing on drug development and medical trends | $2M | 8 mo ago | — | Carl Wild Founder & CEO | — | — |
| 46 | Zeteo Tech Manufacturer of biological mass spectrometers | $2M | 9 mo ago | 19 19 → 20 (+5%) · sector median +28% | — | — | — |
| 47 | Vasoptic Medical Developing non-invasive, dynamic retinal blood flow imaging systems | $2M | 13 mo ago | 2 | Abhishek Rege Co-Founder & President | — | — |
| 48 | Silvec Developer of RNA-based genetic breeding solutions for plants | $2M | 12 mo ago | 26 26 → 13 (-50%) · sector median +28% | Anne Simon Co-Founder | — | — |
| 49 | Polaris Genomics Developer genomic-based diagnostics and therapeutics for neurological conditions | $800K | 9 mo ago | 10 | Tshaka Cunningham Co-Founder | — | — |
| 50 | BSD Developer of multigenic therapies for complex diseases | $705K | 3 mo ago | 7 | Thomas Reed Founder & CEO | — | — |
Top 12 Life Sciences companies in Maryland
#1
Series B · Baltimore, Maryland · founded 2019 · 197 employees$331.6Mraised▾
Series B · Baltimore, Maryland · founded 2019 · 197 employees
Provider of DNA sequencing for cancer detection. The company's platform uses artificial intelligence and whole genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients with cancer.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Funding
top 17%Patents
top 24%AI
top 28%Moat
top 28%Innovation
top 32%Talent
top 42%Funding: Raised $332M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) · Last round Conventional Debt (Dec 2025)
Patents: 52 patents matched (strict assignee match) · 52 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
AI: Holds AI/ML patents (G06N-family CPC) · Product described with: artificial intelligence
Audience (LinkedIn): 20k LinkedIn followers — 11.0% of this cohort's audience
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Senior Data Scientist, Computational Biology
Activity (LinkedIn): 1 partnerships · 3 awards (incl. OSF HealthCare) announced in 12 mo
Funding rounds
- Dec 2025Conventional Debt$34.3M
- Jun 2024Series B—
- Jul 2022Series B$225M
- Jan 2021Series A$101.1M
Founders & team
Investors
Merck Global Health Innovation Fund, DFJ Growth, Lilly, Point72, Brown Advisory, Point Field Partners
#2
Series C · Rockville, Maryland · founded 2016 · 22 employees$72.3Mraised▾
Series C · Rockville, Maryland · founded 2016 · 22 employees
Developer of portable MRI for the cancer diagnostics market. Its platform technology enables collection and analysis of imaging data points for prostate imaging in a shorter time frame than conventional MRIs. First application is prostate cancer screening in patients with elevated PSA levels to determine the need of an invasive biopsy.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 7k LinkedIn followers — 4.0% of this cohort's audience
Funding rounds
- Mar 2026Series C$26.8M
- 2025Series C—
- Mar 2024Series C$41.9M
- Feb 2024Conventional Debt$550K
Founders & team
Investors
MicroPort Orthopedics, Kineticos, Huami, Zepp Labs, Medical Technology Venture Partners, Almond Tree Capital
Tech stack
Apache Http ServerAstraBluehostBootstrapCdnjsCloudflare
#3
Public · Gaithersburg, Maryland · founded 2007 · 88 employees$267Mraised▾
Public · Gaithersburg, Maryland · founded 2007 · 88 employees
Developer of RNA-based therapeutics for the treatment of cancer and fibrosis disease. The company has proprietary delivery technologies, a polypeptide nanoparticle RNAi platform and GalNAc RNAi platform, GalAhead, to develop drug candidate pipeline which include STP122G for cardiovascular disease treatment. It also, develops pipeline of drugs for cancers, skin conditions, fibrosis-related diseases, antiviral and cardiometabolic diseases, and medical aesthetics.
Fliar Intelligence Index™ 80how this company ranks against its industry peers
Patents
top 14%Funding
top 15%Innovation
top 17%Growth
top 28%Moat
top 35%Market
top 46%Patents: 277 patents matched (strict assignee match) · 191 filings since 2022 vs 63 in 2017-21 · Latest publication 2026
Funding: Raised $267M across 14 rounds · 14 rounds over 19 yrs (0.7/yr) · Last round Post IPO (Sep 2025)
Innovation: 277 patents (top 8% of patent-holders) · 191 filings since 2022 vs 63 in 2017-21
Audience (LinkedIn): 7k LinkedIn followers — 4.1% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Sep 2025Post IPO$17.7M
- Jul 2021Series E$105M
- Oct 2020Series D$105M
- Jul 2019Series C$25M
Founders & team
Investors
Maryland, Rich Yield Capital, Rotating Boulder Fund, NIH SBIR/STTR, Yuexiu Group, Sangel Biomedical Venture Capital
#4
Public · Rockville, Maryland · founded 1991 · 234 employees$69.5Mraised▾
Public · Rockville, Maryland · founded 1991 · 234 employees
Developer of therapeutics for the treatment of cancer. The company's pipeline includes ENMD-2076, a selective angiogenic kinase inhibitor, and 2ME2 for autoimmune disorders. ENMD-2076 has received orphan drug designation from the FDA for the treatment of ovarian cancer, multiple myeloma, acute myeloid leukemia and hepatocellular carcinoma.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Product
top 19%Funding
top 26%Growth
top 36%Innovation
top 38%Fin. health
top 43%Market
top 46%Product: 3 distinct product lines · Company stage: Public
Funding: Raised $69.5M across 5 rounds · 5 rounds over 20 yrs (0.2/yr) · Last round Post IPO (Dec 2025)
Growth: Headcount 189 → 234 (+24%) across vintages · Revenue +99% YoY · Fresh capital in last 24 mo
Audience (LinkedIn): 1k LinkedIn followers
Funding rounds
- Dec 2025Post IPO$5M
- Jun 2024Post IPO$15M
- Jan 2016Post IPO$10.3M
- Feb 2012Post IPO$10M
Investors
Accel, Emerging Technology Partners, IDG Capital, Aravis, Kleiner Perkins
Tech stack
AccessibeBluehostDudaHstsJqueryJquery Migrate
#5
Funding Raised · Rockville, Maryland · founded 2003 · 77 employees$187.8Mraised▾
Funding Raised · Rockville, Maryland · founded 2003 · 77 employees
Developer of whole-parasite malaria vaccines for infectious diseases. The company is developing protective vaccines against malaria and plasmodium falciparum infection in humans.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Funding
top 23%Patents
top 33%Moat
top 41%Innovation
top 46%Growth
top 47%Market
bottom 44%Funding: Raised $188M across 44 rounds · 44 rounds over 21 yrs (2.1/yr) · Last round Grant (prize money) (Sep 2025)
Patents: 134 patents matched (strict assignee match) · 16 filings since 2022 vs 46 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 1/10 · IP moat: 134 patents
Funding rounds
- Sep 2025Grant (prize money)$2M
- Sep 2025Grant (prize money)$5.9M
- Jul 2025Grant (prize money)$3M
- Feb 2025Grant (prize money)$988.8K
Investors
NIAID, Gates, HHS
Tech stack
Animate.CssBootstrapContact Form 7Core-JsFont AwesomeGoogle Analytics
#6
Series B · Baltimore, Maryland · founded 2021$41.5Mraised▾
Series B · Baltimore, Maryland · founded 2021
A medical technology company developing drug delivery systems to treat brain diseases and disorders. It is a technology company that develops implantable devices for brain tumor treatment. Its flagship product, NeuroPASS, is a drug delivery system designed to bypass the blood-brain barrier using precise flow rate of medication directly to the brain for the treatment of aggressive brain tumors, Alzheimer’s, and Parkinson’s disease.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Patents
top 23%Innovation
top 28%Funding
top 31%Moat
top 34%Talent
top 38%Global
top 48%Patents: 47 patents matched (strict assignee match) · 47 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Innovation: 47 patents (top 32% of patent-holders) · 47 filings since 2022 vs 0 in 2017-21
Funding: Raised $41.5M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) · Last round Series B (Jan 2026)
Funding rounds
- Jan 2026Grant (prize money)$1M
- Jan 2026Series B$19M
- Jun 2024Grant (prize money)$1M
- Sep 2022Series A$20M
Founders & team
Investors
Mumbai Angels, Lumis Partners, Maryland
#7
Series B · Rockville, Maryland · founded 2008 · 31 employees$52.8Mraised▾
Series B · Rockville, Maryland · founded 2008 · 31 employees
Developer of lentivirus therapies for the treatment of cancer and other chronic human diseases. The company has developed drugs using its delivery platform. The product pipeline includes a liver cancer therapeutic lentivirus and an AIDS therapeutic lentivirus, as well as Parkinson’s disease therapeutic lentivirus, and a familial dysautonomia therapeutic lentivirus.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 24%Patents
top 31%Moat
top 35%Talent
top 35%Innovation
top 37%Growth
top 40%Funding: Raised $52.8M across 10 rounds · 10 rounds over 13 yrs (0.8/yr) · Last round Series B (Nov 2025)
Patents: 228 patents matched (strict assignee match) · 90 filings since 2022 vs 138 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 4/10 · IP moat: 228 patents · 10 curated direct competitors tracked
Funding rounds
- Nov 2025Series B$310K
- Apr 2022Series B$50M
- Nov 2015Series A$1.2M
- Sep 2015Grant (prize money)$232.2K
Founders & team
Investors
NIH, Ride wave ventures, HHS, Gaingels, Alumni Ventures
Tech stack
AddtoanyAddtoany Share ButtonsAmazon SesAmazon Web ServicesBeaver BuilderCdnjs
#8
Public · Cambridge, Maryland · founded 2017 · 5 employees$8.4Mraised▾
Public · Cambridge, Maryland · founded 2017 · 5 employees
Developer of therapies for treating cancer. The lead candidate of the company acts on HER-2 a member of the human epidermal growth factor receptor such as HER/EGFR/ERB which is used to treat Osteosarcoma. Also, developing folate receptor-targeted TDC for ovarian, pancreatic, lung, and others.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 1k LinkedIn followers
Funding rounds
- Mar 2026Post IPO$2M
- Jan 2026Post IPO$3.5M
- Sep 2025Post IPO$3.8M
- Jun 2025Post IPO$4.2M
Founders & team
Investors
K20 Fund
Tech stack
AosApache Http ServerBootstrapCdnjsCivicthemeCloudflare
#9
Series A · Rockville, Maryland · founded 2005 · 51 employees$25.3Mraised▾
Series A · Rockville, Maryland · founded 2005 · 51 employees
Developer of platelet-derived therapeutics to address bleeding control and hemostasis challenges. The company develops stabilized cellular products like freeze-dried hemostatic agents and cryopreserved platelets targeting trauma, surgery, and military applications.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers
Funding rounds
- Nov 2025Conventional Debt$3M
- Aug 2022Series A$5M
- Apr 2021Series A$15M
- Jun 2017Series A$3M
Founders & team
Investors
Simcah Management, Maryland Venture Fund, Military Health, Circadian Ventures
Tech stack
WebflowJqueryGoogle AnalyticsFont Awesome
#10
Series C · Baltimore, Maryland · founded 2007 · 6 employees$60.3Mraised▾
Series C · Baltimore, Maryland · founded 2007 · 6 employees
Discovering and developing innovative biologics for immune disorders and cancers. The company focuses on modulating the immune system to create new treatment options for autoimmune diseases and cancers. They are advancing multiple drugs through clinical trials, including recombinant Fc fusion proteins designed to mimic or inhibit specific immune pathways. Their approach involves a team of talented scientists, board members, scientific advisors, and a network of global thought leaders. They aim to make a significant difference in the lives of individuals with immune disorders through innovative drug discovery and development. Their expertise lies in biologics, clinical trials, drug design, protein production, purification, and analysis, targeting autoimmune diseases and cancers.
Fliar Intelligence Index™ 22how this company ranks against its industry peers
Funding
top 21%Moat
top 21%Product
top 25%Patents
top 31%Innovation
top 33%Global
bottom 36%Funding: Raised $60.3M across 12 rounds · 12 rounds over 16 yrs (0.8/yr) · Last round Series C (Aug 2025)
Moat: Editorial + unicorn rating 7/10 · IP moat: 246 patents
Product: 5 distinct product lines · Company stage: Series C
Funding rounds
- Aug 2025Series C$11M
- Nov 2024Series C$5.3M
- Jul 2023Series C$5.4M
- Jun 2021Series C$11.5M
Investors
Brace Pharma Capital, Pfizer, First In Ventures, RDA Ventures, SAISO Partners, Garden Street Holdings
Tech stack
WordpressMysqlPhpYoast SeoApache Http ServerLightbox
#11
Public · Gaithersburg, Maryland · founded 2001 · 10 employees$64.6Mraised▾
Public · Gaithersburg, Maryland · founded 2001 · 10 employees
Developer of regenerative products for wound care. The company focuses on regenerative therapies to primarily address the areas of wound care, inflammation, and angiogenesis. Its proprietary technology Aurix is a biodynamic hematogel that is an auto platelet and plasma therapy system. It has been approved by the FDA for use in the management of wounds and ulcers of all types and severities.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Growth
top 11%Funding
top 24%Talent
top 45%Fin. health
top 50%Moat
bottom 38%Global
bottom 37%Growth: Revenue +143% YoY · Fresh capital in last 24 mo
Funding: Raised $64.6M across 18 rounds · 18 rounds over 16 yrs (1.1/yr) · Last round Post IPO (Jul 2025)
Talent: 2 named leaders on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- Jul 2025Post IPO$791.4K
- Sep 2024Post IPO$849.1K
- May 2024Post IPO$650.9K
- Dec 2023Post IPO$962.5K
Founders & team
Investors
Maryland Department of Commerce, Anson Group, Aldagenholdings, MidCap Financial
Tech stack
WordpressMysqlPhpWp RocketDiviYoast Seo
#12
Series B · Rockville, Maryland · founded 2020 · 41 employees$52.3Mraised▾
Series B · Rockville, Maryland · founded 2020 · 41 employees
Developer of immunotherapy for cancer patients. The lead product, CD24Fc reduces disease progression to death or respiratory failure. The lead candidate ONC-392 is a next-generation anti-CTLA-4 antibody, other candidates targeting cancer cells through chimeric antigen receptors T cells, bi-specific antibodies, and antibody-drug conjugates cells.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
Patents
top 17%Innovation
top 21%Funding
top 28%Moat
top 33%Global
bottom 43%Market
bottom 42%Patents: 128 patents matched (strict assignee match) · 115 filings since 2022 vs 13 in 2017-21 · Latest publication 2026
Innovation: 128 patents (top 15% of patent-holders) · 115 filings since 2022 vs 13 in 2017-21
Funding: Raised $52.3M across 2 rounds · 2 rounds over 6 yrs (0.3/yr) · Last round Series B (Oct 2025)
Audience (LinkedIn): 3k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Research Associate
Activity (LinkedIn): 1 product launches · 1 awards announced in 12 mo
Funding rounds
- Oct 2025Series B$50M
- Apr 2020Grant (prize money)$2.3M
Investors
HHS, HM Capital, 3E Bioventures Capital, Kaitai Capital Management, GBA Fund, HM Venture Partners
Funding & investor landscape
$11.5Btotal disclosed funding
301companies funded
1,546disclosed rounds
1rounds last 90 days
Most active investors
Abell Foundation11 rounds
Notable founders
Victor Velculescu
Founder and Board of Directors · Delfi Diagnostics
Susan Tousi
CEO · Delfi Diagnostics
Irving Weinberg
Co-Founder · Promaxo
Michael Bartholomew
Co-Founder · Promaxo
Patrick Lu
President and CEO · Sirnaomics
Chad Gordon
Founder & CMO · CraniUS
Michael Maglin
CEO · CraniUS
Jeff Galvin
Chief Executive Officer · American Gene
Paul Romness
CEO · OS Therapies
Richard Cliff
COO · Cellphire Therapeutics
Mike Gaffney
CEO · Cellphire Therapeutics
Paul Mintz
· Nuo Therapeutics
Prism market signals · United States · country-scoped Prism corpus, 1,465,538 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN MARYLAND · Health & Bio
How research on Biotechnology in Maryland is moving
A read on the academic research around Biotechnology in Maryland — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 57 papers.
University of Maryland's institutions lead Maryland's biotechnology research with an optimistic tone (0.48), focusing dominantly on CRISPR/genetic engineering and biosensors, with breakthroughs outpacing concerns nearly fourfold.
57 papers · stance +0.48 · 49% breakthrough · 13% concern
top institutions
- University of Maryland, Baltimore25
- University of Maryland, College Park22
- University of Maryland, Baltimore County6
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center2
- Maryland Department of Health2
leading researchers
Brittany Hazzard · D Sun · Dipanwita Dutta Chowdhury · Eddie Luidy Imada · Evan Benke · Francesca A. Carrieri
prism intelligence · tone & topics
88% positive · 2% critical tone
HealthPharmaceuticalsMedical ResearchAgricultureBiologyClinical Trials
▲
Breakthroughs22 · 39%
▲ 33%→36% share
▲1.1× share momentum0 median citations73% since 2021mostly empirical
Cell culture research is newly emerging and rising — 3 papers signal a brand-new focus within Maryland biotech breakthroughs.
rising sub-themes (early→recent)
- Cell culture3
- Limiting2
- Bacillus thuringiensis2
- Epithelium2
- In vivo2
Newly emergingCell culture 0→3
Landmark Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine · 926 cites
◆
Advancements17 · 30%
▼ 33%→31% share
▼0.9× share momentum0 median citations82% since 2021mostly empirical
Prostate cancer research is intensifying — 2 papers driving advancements even as the segment's field-share cooled from 33% to 31%.
rising sub-themes (early→recent)
- Prostate cancer2
- Recombinase Polymerase Amplification1
- Multiple displacement amplification1
- Loop-mediated isothermal amplification1
- Nucleic acid1
Landmark Nrf2 Protein Up-regulates Antiapoptotic Protein Bcl-2 and Prevents Cellular Apoptosis · 537 cites
▼
Concerns6 · 11%
▼ 17%→9% share
▼0.5× share momentum0 median citations67% since 2021mostly reviews
Antibiotic resistance and antimicrobial research persist with 2 papers each, despite concerns field-share dropping sharply from 17% to 9%.
rising sub-themes (early→recent)
- Antibiotic resistance2
- Antimicrobial2
- Aquaculture1
- Population1
- Antibiotics1
Landmark A review of Listeria monocytogenes: An update on outbreaks, virulence, dose-response, ecology, and risk assessments · 798 cites
Common questions
How many Life Sciences companies are there in Maryland, United States?
Radar tracks 516 indexable Life Sciences companies headquartered in Maryland, United States that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Maryland, United States?
The Life Sciences companies in Maryland, United States on this list have raised a combined $11.5B in disclosed equity funding across 301 funded companies.
Which is the highest-funded Life Sciences company in Maryland, United States?
Novavax is the highest-funded Life Sciences company in Maryland, United States, with $2.7B in disclosed equity funding.
How many Life Sciences companies in Maryland, United States are funded?
301 of the 516 Life Sciences companies in Maryland, United States on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Maryland, United States?
None of the Life Sciences companies in Maryland, United States on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Maryland, United States Life Sciences companies?
The most active investors in Maryland, United States Life Sciences companies on this list include HHS, TEDCO, Business Innovation Network, NIH, National Science Foundation.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.